28bio Endurance Study meets primary endpoint — CNS-3D brain organoids successfully predict clinical seizure liability
Summary
28bio announced that their Endurance Study met its primary endpoint, demonstrating that their CNS-3D brain organoid platform successfully predicts clinical seizure liability of drug candidates. The study validated that seizure-inducing drugs produced seizure-like electrical activity in 28bio's brain organoids before first-in-human studies, establishing organoid-based CNS safety screening as a validated preclinical toxicology tool. The result directly challenges the standard practice of relying on animal models (which have poor predictive validity for human CNS seizure liability) for drug safety screening.
Why it matters
28bio's validated seizure prediction in brain organoids addresses one of drug development's most costly failures — CNS drugs that show unexpected seizure liability in humans after passing animal preclinical safety studies. If organoid screening becomes standard practice, it could prevent the clinical failures that cost billions annually and eliminate the ethical burden of extensive animal CNS toxicology testing.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial